Caricamento...
P17.45 CARBOPLATIN ALONE AND IN COMBINATION WITH BEVACIZUMAB IN A 5MG/KG EVERY-3-WEEK SCHEDULE, IN PATIENTS WITH RECURRENT GLIOBLASTOMAS: A SINGLE CENTER EXPERIENCE
PURPOSE: Carboplatin (CDDP) and Bevacizumab (BEV) are active in GBM with different profiles of toxicity. In a previous report, we have demonstrated the efficacy of Bevacizumab in a 5mg/kg every 3 week schedule We investigated the efficacy of BEV in combination with CDDP vs CDDP alone in patients wit...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185743/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.374 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|